By Josh Beckerman
Sydney-based Kazia Therapeutics plans to trade solely on Nasdaq and delist its securities from the Australian Securities Exchange.
According to a Friday filing with the Securities and Exchange Commission, the oncology-focused drug company requested trading halts of its American depositary shares and its ASX-listed shares pending a company announcement. It expects to make the announcement to ASX before the commencement of normal trading on Tuesday.
Before the late Thursday U.S. halt, ADSs were down 6.5% after hours to 89 cents following a 4.5% increase in the regular session.
Write to Josh Beckerman at [email protected]
Read the full article here